eXoZymes Achieves 100-Fold Scale-Up of NCT Production with 99% Conversion Efficiency Using Cell-Free Enzyme Platform
核心洞察
eXoZymes (搜索) successfully scaled up N-trans-caffeoyltyramine (NCT) production by 100-fold using their proprietary exozyme-based, cell-free biomanufacturing platform while maintaining over 99% feedstock conversion efficiency.
The scale-up was conducted under standardized protocols by partner Cayman Chemical (搜索), demonstrating the robustness and transferability of the exozyme technology for commercial biomanufacturing applications.
This breakthrough validates that cell-free enzyme systems can overcome traditional biomanufacturing limitations and opens opportunities for producing molecules previously constrained by conventional manufacturing approaches.
eXoZymes (搜索) Inc. (NASDAQ:EXOZ) announced a major breakthrough in biomanufacturing scalability with the successful 100-fold scale-up of N-trans-caffeoyltyramine (NCT) production using their proprietary exozyme-based platform. The company achieved an exceptional conversion rate of over 99% from feedstock to product, marking a pivotal milestone for cell-free enzyme technology in commercial applications.
Breakthrough in Biomanufacturing Scale-Up
The scaled reaction maintained exceptionally high conversion efficiency, demonstrating near-complete transformation of input feedstock into target product under large-volume operating conditions. This performance confirms that the exozyme-driven process not only scales linearly but can match or exceed conversion levels observed at smaller scales.
"Scaling a complex biocatalytic reaction by 100× while sustaining high feedstock conversion strengthens our belief that exozymes (搜索) will form the foundation of the next generation of biomanufacturing," said Michael Heltzen, CEO of eXoZymes. "We're very enthusiastic about this progress and see it as an important inflection point in demonstrating that cell-free, enzyme-driven systems can be engineered to operate reliably at scale."
Partnership Validates Technology Robustness
The batch production was executed using standardized protocols under partner-operated conditions by Cayman Chemical (搜索), emphasizing the robustness, transferability, and scalability of the process and technology. This collaboration underscores the commercial viability of the exozyme platform beyond laboratory settings.
Dr. Tyler Korman, CSO of eXoZymes (搜索), emphasized the significance of the achievement: "Scaling while preserving reaction performance has historically been challenging, and this outcome supports the growing body of evidence that cell-free enzyme production pathways - aka exozymes systems - can overcome fundamental limitations associated with traditional biomanufacturing approaches. Achieving over 99% conversion at scale is a significant validation of our exozyme biosolution - both from a scientific as well as a commercial point of view."
Technology Platform and Applications
Exozymes (搜索) are advanced enzymes enhanced through AI and bioengineering designed to function in bioreactors without requiring living cells. The technology aims to replace toxic petrochemical processes and inefficient biochemical extraction methods with sustainable and scalable biosolutions that transform biomass into essential chemicals, nutraceuticals, and medicines.
By eliminating the cellular constraints that typically limit enzyme-driven reactions, exozyme biosolutions address the scaling bottleneck that has historically hampered commercial success in the synthetic biology space. This positions exozymes (搜索) as a potential foundation for next-generation biomanufacturing.
Next Steps and Future Analysis
Cayman Chemical (搜索) and eXoZymes (搜索) are currently collaborating on the isolation process for NCT and analyzing data from the scale-up experiment. Additional technical details are expected to be published in a subsequent press release following completion of downstream analysis and NCT extraction. Due to the magnitude of the work and upcoming holidays, this additional information is not expected until early 2026.
The successful scale-up opens new possibilities for producing molecules that have historically been constrained by traditional manufacturing approaches, potentially transforming how complex biochemicals are manufactured at commercial scale.